APOE and Alzheimer disease: We propose a mechanism for NTD-mediated ApoE aggregation that (i) effectively explains the high aggregation propensity of ApoE4; (ii) explains an unequal efficacy of tramiprosate in AD patients with different ApoE genotypes; and (iii) provides a validated therapeutic target for AD drug development.